focus -WSS

focus

author：knowledge 2025-09-05 18:33:11 - browse：6163

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The health care issue Democrats can’t solve: hospital reform

WSS

After Sarepta trial failure, Duchenne families brace for more debate

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Why Charlie Gard's case is so disturbing to Americans

Chan Zuckerberg Biohub Chicago to focus on inflammation

VC firm General Catalyst wants to buy a health system

The health care issue Democrats can’t solve: hospital reform

focus

focus

focus

Hollywood unions extend contract negotiations for actors

Life sciences investors close nearly $6 billion in new funds

Hollywood unions extend contract negotiations for actors

FDA panel signals lack of confidence in Amgen cancer drug data

Peter Hotez and the public health issue of online harassment

VC firm General Catalyst wants to buy a health system

Malaria cases in Florida and Texas: Here’s what you need to know

Why Charlie Gard's case is so disturbing to Americans

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Chan Zuckerberg Biohub Chicago to focus on inflammation

entertainment

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Kidney transplant patients stopped immunosuppressants in trial

When women are denied an abortion, their children fare worse than peers

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Bill would allow buprenorphine prescription for addiction via telehealth

3 questions for the future of Biden's cancer moonshot

leisure time

hotspot

entertainment

leisure time